Discover the potential of Ispire's innovative cannabis products and holistic solutions, a hidden gem in a competitive market with room to grow.

Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), a multi-asset, clinical stage, disease-agnostic life science company delivering an efficient model for compound development, ...

Applications are based on data from the DEVOTE study, which demonstrate the potential for the investigational higher dose regimen of nusinersen to advance the treatment of SMA ...

MaxCyte Inc. (NASDAQ: MXCT) is a global developer of next-generation cell therapies. They provide crucial technology for cell ...

NDAQ:ZLAB) Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell ...

Exelixis, Inc. (NASDAQ:EXEL), currently trading near $33, continues to build on the success of its flagship product ...

Inhibrx Biosciences , Inc. (NASDAQ:INBX), a clinical-stage biopharmaceutical company valued at $205.41 million, is navigating a critical phase in its development as it advances its oncology pipeline.

Michael Benkowitz, President and COO of United Therapeutics Corp (NASDAQ:UTHR), recently executed a series of stock transactions involving the company's common stock. On January 21, Benkowitz sold ...

Beta Bionics (BBNX), a maker of insulin delivery devices, has disclosed terms for an upsized $113M initial public offering. In its latest SEC filing, the company said it was planning to offer 7.5M ...

Nuvalent, Inc. shares have fallen approximately 30% after promising updates on its two lead NSCLC candidates rallied the ...

MeiraGTx's financials show $125 million in cash, but additional funding will be needed within the next 12 months. Click for ...